FDA Approves METHADONE HYDROCHLORIDE — Hikma Pharmaceuticals USA Inc.

# FDA Approves Methadone Hydrochloride Oral Formulation for Hikma Pharmaceuticals Hikma Pharmaceuticals USA Inc. received FDA approval for its oral methadone hydrochloride formulation (ANDA088109), expanding the company's portfolio in the established opioid maintenance treatment market where generic competition remains limited. The approval positions Hikma to capture additional market share in the critical addiction treatment segment, which continues to see steady demand despite ongoing regulatory scrutiny of opioid therapies.